Literature DB >> 16898578

Treatment of hypertriglyceridemia.

Warren H Capell, Robert H Eckel.   

Abstract

Hypertriglyceridemia is a disorder commonly encountered in clinical practice. Treatment of this condition aims to prevent the major complications of hypertriglyceridemia, which differ depending on whether triglyceride elevations are moderate or severe. This review discusses the pathophysiology and clinical consequences of hypertriglyceridemia and outlines treatment approaches based on the degree of triglyceride elevation. Special consideration is given to clinical trials using medications that primarily target triglycerides.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898578     DOI: 10.1007/s11892-006-0040-9

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

1.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man.

Authors:  J D Brunzell; W R Hazzard; D Porte; E L Bierman
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

2.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Authors:  Robert Ratner; Ronald Goldberg; Steven Haffner; Santica Marcovina; Trevor Orchard; Sarah Fowler; Marinella Temprosa
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

3.  Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease.

Authors:  Paul N Hopkins; Lily L Wu; Steven C Hunt; Eliot A Brinton
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

4.  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

Authors:  Elaine Chiquette; Gilbert Ramirez; Ralph Defronzo
Journal:  Arch Intern Med       Date:  2004-10-25

5.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

6.  Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

Authors:  Alexander Tenenbaum; Michael Motro; Enrique Z Fisman; David Tanne; Valentina Boyko; Solomon Behar
Journal:  Arch Intern Med       Date:  2005-05-23

Review 7.  Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm.

Authors:  Allan D Sniderman
Journal:  Curr Opin Lipidol       Date:  2004-08       Impact factor: 4.776

8.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

9.  Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.

Authors:  P Koskinen; M Mänttäri; V Manninen; J K Huttunen; O P Heinonen; M H Frick
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

Review 10.  Metabolic abnormalities: triglyceride and low-density lipoprotein.

Authors:  Ronald M Krauss; Patty W Siri
Journal:  Endocrinol Metab Clin North Am       Date:  2004-06       Impact factor: 4.741

View more
  1 in total

1.  Glucose tolerance, lipids, and GLP-1 secretion in JCR:LA-cp rats fed a high protein fiber diet.

Authors:  Raylene A Reimer; James C Russell
Journal:  Obesity (Silver Spring)       Date:  2008-01       Impact factor: 5.002

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.